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Fgf8 is required for normal development of the nasal region. Here, we have used a candidate approach to identify genes that
are induced in chick nasal mesenchyme in response to FGF signaling. Using an explant culture system, we show that
expression of the transcription factors Tbx2, Erm, Pea3, and Pax3, but not Pax7, in nasal mesenchyme is regulated by
ectodermal signals in a stage-dependent manner. Using beads soaked in recombinant FGF protein and an FGF receptor
antagonist, we furthermore demonstrate that FGF signaling is necessary and sufficient for expression of Tbx2, Erm, Pea3,
and Pax3, but has no effect on Pax7 expression. We also show that, within the nasal mesenchyme, competence to respond
to FGF signaling is initially widespread and uniform but becomes restricted to regions normally exposed to FGF at later
stages of development, coincident with changes in FGF receptor expression. Finally, we provide evidence that FGF8 also
regulates Erm and Pea3 expression in the nasal placodes. Together, these results identify Tbx2, Erm, Pea3, and Pax3 as
downstream targets of FGF signaling in the facial area and suggest that these genes may mediate some of the effects of FGF8
during development of the nasal region. © 2002 Elsevier Science (USA)
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chick.INTRODUCTION
The vertebrate face is a complex structure that consists of a
large variety of diverse tissues in precisely defined spatial
arrangements. During embryogenesis, the face develops from
buds of tissue, the facial primordia, which surround the
primitive mouth and the nasal placodes. The frontonasal
mass, the lateral nasal process, and the maxillary processes
grow out and partially fuse to form the upper jaw and nasal
region in mammals and the upper beak in birds, while the
mandibular primordia give rise to the lower jaw or beak. All
facial primordia initially consist of a core of undifferentiated
mesenchyme covered by ectoderm. The mesenchyme con-
tains cells of neural crests and cranial mesodermal origin.
Neural crest-derived cells give rise to the facial skeleton,
whereas mesodermal cells mainly form facial muscles (Couly
et al., 1992, 1993; Noden, 1978, 1983, 1988).
Outgrowth of all facial primordia depends on epithelial
mesenchymal interactions, and removal of the epithelium
truncates facial development (Wedden, 1987). In the first
branchial arch (BA1), where these tissue interactions have
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All rights reserved.been examined in more detail, numerous studies have now
provided evidence that ectodermal signals regulate mesen-
chymal cell proliferation, survival, patterning, and differen-
tiation. In turn, signals from the mesenchyme influence
development of the ectoderm (for a review, see Francis-
West et al., 1998; Jernvall and Thesleff, 2000). These studies
also demonstrated that maxillary and mandibular mesen-
chyme can respond differently to the same signals. There-
fore, the specificity of the response seems to be a property
intrinsic to the mesenchymal cells and might be related to
the origin of the neural crest cells along the anterior–
posterior axis (Ferguson et al., 2000).
Among the molecules implicated as epithelial signals
regulating gene expression in BA1 mesenchyme are mem-
bers of the FGF family, in particular FGF8 (reviewed by
Jernvall and Thesleff, 2000). Studies in which isolated
mandibular mesenchyme was cultured in contact with
beads soaked in FGF8 demonstrated that FGF8 can substi-
tute for the ectoderm to promote cell survival, stimulate
proliferation, and induce and maintain expression of a
variety of genes. Several of these genes (e.g., Pax9, Dlx1, and
Dlx2) are known to be required for normal mandibular and
tooth development (Neubu¨ser et al., 1997; Peters et al.,To whom correspondence should be addressed. Fax: (43)-1-
1998; Thomas et al., 1997, 2000). Tissue-specific gene-
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targeting experiments inactivating Fgf8 in BA1 ectoderm
have recently demonstrated that FGF8 has a dual function
during BA1 development. It promotes mesenchymal cell
survival and induces a developmental program required for
BA1 morphogenesis (Trumpp et al., 1999).
Patterning and morphogenesis of the prospective midfa-
cial and nasal region have so far received much less atten-
tion, even though this region is frequently affected in
human craniofacial malformation syndromes, such as cleft
lip/cleft palate, which occur with a frequency of 1 in 1000
newborns (Derijcke et al., 1996). As in BA1, outgrowth of
frontonasal mesenchyme requires ectodermal signals, and
many of the same signaling molecules implicated in BA1
patterning are also expressed in midfacial ectoderm (Wed-
den, 1987). In particular, Fgf8 and six other members of the
FGF family are expressed in overlapping domains in the
prospective nasal region, and Fgf8 expression correlates
with areas of high cell proliferation and expansion in
frontonasal mass mesenchyme (Bachler and Neubu¨ser,
2001; McGonnell et al., 1998). In addition, FGF8 has re-
cently been implicated as medial signal during olfactory
pathway development (LaMantia et al., 2000). Tissue-
specific inactivation of Fgf8 in midfacial ectoderm and the
underlying brain results in severe facial defects, including a
midfacial cleft, indicating that Fgf8 is required for develop-
ment of that region (A. Leibbrandt and M. Repitz, unpub-
lished observations). However, in contrast to BA1, little is
known about the genes induced in response to FGF signal-
ing in the nasal region, and most of the genes known to be
induced by FGF in BA1 are not expressed in that area.
In this study, we have used a candidate-gene approach
and an in vitro explant culture system to identify a set of
target genes of FGF signaling in chick nasal mesenchyme
that may mediate some of the effects of FGF8 during
development of the nasal region. In this, we have focused on
the T-box, Pax, and Pea3 transcription factor families,
which have been implicated with functions in patterning,
the regulation of cell proliferation, cell survival, and cell
differentiation during development (Smith, 1999; de
Launoit et al., 1997). All three gene families include mem-
bers that have previously been shown to be regulated by
FGF signaling in other contexts (Isaacs et al., 1994; Neu-
bu¨ser et al., 1997; Peters et al., 1998; Trumpp et al., 1999;
Munchberg and Steinbeisser, 1999). Furthermore, the T-box
gene Tbx2, the Pax genes Pax3 and Pax7, and the Ets genes
Pea3 and Erm have been reported to be expressed during
craniofacial development (Chapman et al., 1996; Chotteau-
Lelievre et al., 1997; Gibson-Brown et al., 1998; Mansouri
et al., 1996). Here, we show that expression of Tbx2, Erm,
Pea3, and Pax3 is regulated in response to FGF signaling.
MATERIALS AND METHODS
Embryos
Fertilized chicken eggs were obtained from a local farmer (Kern
chicken farm, Alland, Austria). Eggs were incubated at 38  1°C,
and embryos were staged according to Hamburger and Hamilton
(1951).
Explant Culture, Tissue Recombination, and Bead
Implantation
All dissections were performed in cold L15 medium (Gibco BRL)
by using electrolytically sharpened tungsten needles. To obtain
tissue for explant culture, the prospective midfacial region consist-
ing of forebrain, facial mesenchyme, and facial ectoderm including
the nasal placodes, was isolated as schematically shown in Fig. 1.
For the separation of tissue layers, freshly explanted tissue was
incubated on ice in 2.5% pancreatin (Gibco BRL) for 20 (stage
18–22 embryos) to 25 (stage 23–24 embryos) minutes, washed three
times with cold L15 medium supplemented with 10% horse serum,
and then incubated on ice in serum-supplemented L15 medium for
10 min. Unless otherwise stated, the forebrain tissue was removed
by using 27-gauge injection needles followed by further separation
FIG. 1. Dissection of nasal explants. The encircled region (dashed
line) was excised with sharpened tungsten needles, resulting in an
explant initially consisting of ectoderm, mesenchyme, and brain
tissue. After incubation in pancreatin, the brain, and as required
also the ectoderm, was removed. Explants consisting of ectoderm
and mesenchyme (A), mesenchyme (B), or mesenchyme on which a
ball of ectoderm, or beads soaked in recombinant proteins or PBS
had been placed (C) were then cultured on filters floating on culture
medium.
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of tissue layers as required for the particular experiment. Recom-
bination of facial mesenchyme and facial ectoderm was performed
as described by Vainio et al. (1993).
For focal application of recombinant proteins to facial explants,
heparin acrylic beads (Sigma) were soaked in recombinant proteins
and applied to facial explants as previously described (Neubu¨ser et
al., 1997). The following recombinant proteins were used: human
FGF4 (50 g/ml to 1 mg/ml), human FGF5 (1 mg/ml), mouse FGF8b
(1 mg/ml), human FGF9 (1 mg/ml), human FGF10 (1 mg/ml),
human EGF (1 mg/ml), or human IGF1 (1 mg/ml) (all from R&D
Systems, Minneapolis, MN). Su5402 (Calbiochem) was used at 25
M. At the end of the culture period (2–24 h), the explants were
fixed in 4% paraformaldehyde and processed for whole-mount in
situ hybridization.
For bead implantation into the facial area in ovo, a small cut was
introduced into the ectoderm covering the lateral nasal region by
using a tungsten needle. An FGF-soaked bead was then carefully
placed between ectoderm and mesenchyme by using a glass capil-
lary attached to a mouth-controlled pipette. After microsurgery,
the eggs were closed with scotch tape and incubated until the
desired stage.
Each experiment was performed at least twice, but more typi-
cally three to five times, and the total number of specimens
examined for each experimental condition is indicated in Results.
RNA in Situ Hybridization
For whole-mount RNA in situ hybridization, embryos or ex-
plants were fixed, processed, and hybridized according to the
protocol described by Henrique et al. (1995). Digoxigenin-labeled
anti-sense riboprobes were detected with alkaline phosphatase-
coupled anti-digoxigenin antibodies by using BM purple (Boeh-
ringer Mannheim) as the color substrate. All specimens belonging
to the same experiment were processed in parallel, and in each
experiment, specimens hybridized with the same probe were
stained for the same amount of time. Quantitative differences in
expression levels under different experimental conditions were
confirmed by processing the corresponding specimens in the same
tube in at least one additional experiment. The plasmids used to
prepare the antisense riboprobes employed in this study have
previously been described: Fgf8 (Crossley et al., 1996), Pax3, Pax7
(Goulding et al., 1993), Tbx2 (Logan et al., 1998), Pea3, Erm (Lin et
al., 1998), Fgfr1, Fgfr2, and Fgfr3 (Patstone et al., 1993). For
expression analysis in embryos for each probe and stage described,
a minimum of six embryos in at least three independent experi-
ments were examined.
For RNA in situ hybridization on paraffin sections (6 m),
embryos were processed, sectioned, and hybridized with
digoxigenin-labeled riboprobes as described by Neubu¨ser et al.
(1995) with some modifications. A detailed protocol is available
upon request. For each gene and stage, serial sections of at least
three embryos were analyzed.
RESULTS
Expression of Fgf8, Tbx2, Erm, Pea3, Pax3, and
Pax7 during Midfacial Development
As a first step to assess whether Tbx2, Erm, Pea3, Pax3,
and Pax7 might be targets of FGF8 during midfacial devel-
opment, we examined their expression patterns in the nasal
area and compared them with the expression of Fgf8.
At stage 18, Fgf8 is widely expressed in midfacial ecto-
derm between the nasal placodes with slightly higher
expression levels at the medial edge of the placodes (Figs.
2A and 2B). Between stage 18 and stage 20, Fgf8 expression
spreads along the edge of the nasal placodes into the lateral
nasal process and is subsequently downregulated in midfa-
cial ectoderm (data not shown). By stage 24, high levels of
Fgf8 RNA are confined to a horseshoe-shaped domain
surrounding the nasal pits and to a narrow line of ectoderm
connecting the oral limits of both nasal pits (Fig. 2C,
arrowhead).
At all stages analyzed, expression of Tbx2 in the facial
region is restricted to the mesenchyme. At stage 18, Tbx2 is
widely expressed in the midfacial region and becomes
restricted to a horseshoe-shaped region of mesenchyme
around the nasal pits at stage 24 with higher expression
levels in the lateral nasal process (Figs. 2D–2F).
Erm, Pea3, and Pax3 are also widely expressed in facial
mesenchyme at stage 18. In addition, expression of all three
genes is detected in the ectoderm surrounding the nasal
pits. Erm and Pea3 are also expressed within the nasal
placodes (Figs. 2G, 2H, 2J, 2K, 2M, and 2N). At stage 24,
expression of all three genes is upregulated in the mesen-
chyme surrounding the nasal pits with higher expression
levels in the lateral nasal process, whereas expression in the
facial midline has been downregulated. Ectodermal expres-
sion of all three genes at stage 24 is similar to the expression
at stage 18 (Figs. 2I, 2L, and 2O; and data not shown).
Pax7 is expressed in the lateral nasal mesenchyme and in
a stripe of mesenchymal cells extending from the dorsal
midline into the lateral nasal region at stage 18 (Fig. 2P,
arrow, and Fig. 2Q). At stage 24, Pax7 expression is re-
stricted to the lateral nasal process (Fig. 2R).
In summary, this analysis shows that the expression
domains of Tbx2, Erm, Pea3, and Pax3 in the nasal region at
stage 18 considerably overlap with the expression domain
of Fgf8, but extend further laterally. Such an overlap can
also be detected at later stages, when expression of Tbx2,
Erm, Pea3, and Pax3 becomes restricted to the mesen-
chyme around the nasal pits coincident with the restriction
of Fgf8 expression to the ectoderm flanking the nasal pits.
Dependence of Mesenchymal Expression of Tbx2,
Erm, Pea3, Pax3, and Pax7 on Ectodermal Signals
Expression of Tbx2, Erm, Pea3, Pax3, and Pax7 is detect-
able in mesenchyme directly underlying the facial ecto-
derm. In order to test whether this expression is regulated
by signals from the ectoderm, the facial region from stage
18 embryos was dissected and cultured in vitro as schemati-
cally shown in Fig. 1. In explants consisting of facial
ectoderm and mesenchyme, expression of Tbx2 (n 29/29),
Erm (n  16/16), Pea3 (n  21/21), Pax3 (n  17/17), and
Pax7 (n  7/7) was readily detectable after 24 h in culture
(Figs. 3A–3E). If the mesenchyme was cultured without the
ectoderm, expression of Tbx2 (n  17/17), Erm (n  12/12),
Pea3 (n 17/17), and Pax3 (n 11/11) was lost (Figs. 3F–3I).
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Pax7 expression, in contrast, was still detected in the areas
corresponding to the lateral nasal process albeit at a reduced
level (Fig. 3J; n  11/11). In explants from which the
ectoderm was removed and then placed back in contact
with the mesenchyme prior to culture, expression of Tbx2
(n  4/4), Erm (n  4/4), Pea3 (n  5/5), and Pax3 (n  4/4)
was observed in mesenchyme adjacent to the replaced
ectoderm (Figs. 3K–3N). Pax7 expression, however, was not
induced in mesenchyme close to the ectoderm and was only
observed in the lateral nasal region (Fig. 3O, n 9/9). These
results indicate that maintenance of Tbx2, Erm, Pea3, and
Pax3 expression in the nasal mesenchyme requires signals
from the nasal ectoderm, whereas Pax7 expression in lateral
nasal mesenchyme is independent of such signals.
FIG. 2. Expression of Fgf8, Tbx2, Erm, Pea3, Pax3, and Pax7 in the midfacial region of chick embryos at stage 18 and stage 24. (A, C, D,
F, G, I, J, L, M, O, P, R) Whole-mount in situ hybridizations. (B, E, H, K, N, Q) Nonradioactive in situ hybridizations on transverse paraffin
sections, lateral to the left. (A–C) Fgf8 expression is restricted to the facial ectoderm and forebrain (asterisk in C). (D–F) Tbx2 is expressed
in the facial mesenchyme. (G–L) Erm and Pea3 are expressed in the nasal mesenchyme, the nasal placodes and adjacent ectoderm, and the
forebrain. (M–O) Pax3 is expressed in the mesenchyme and the ectoderm surrounding the nasal placodes. (P–R) Pax7 expression is restricted
to the lateral nasal mesenchyme. Fb, forebrain; fnm, frontonasal mass; l, lateral; lnp, lateral nasal process; m, medial; np, nasal placode;
arrowhead, line of Fgf8 expression referred to in the text
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We next examined whether ectodermal signals are still
required to maintain the expression of Tbx2, Erm, Pea3,
Pax3, and Pax7 at later stages of development. For this
purpose, we assayed for the expression of these genes in
facial mesenchyme isolated from stage 24 embryos and
cultured either in the presence or absence of the ectoderm.
In the presence of the ectoderm, Tbx2 (n 14/14), Erm (n
13/13), Pea3 (n  9/9), and Pax3 (n  7/7) expression was
strongly upregulated in the nasal pit area and Pax7 (n 
10/10) expression in the lateral nasal processes (Figs. 3P–
3T). In stage 24 mesenchyme cultured without the ecto-
derm, Tbx2 expression was still detectable but upregulation
of expression in the nasal pit area did not occur (Fig. 3U, n
7/7). Expression of Pea3 (n  6/6) and Pax3 (n  12/12) was
also maintained, but expression of both genes in the region
corresponding to the medial nasal process was reduced or
absent (Figs. 3W and 3X). Erm expression was severely
downregulated and was only detected when explants were
grossly overstained (Fig. 3V; and data not shown; n 
10/10). Pax7 expression, in contrast, was indistinguishable
from expression in explants consisting of ectoderm and
mesenchyme (Fig. 3Y, n  7/7).
Together, these data indicate that the early expression of
Tbx2, Erm, Pea3, and Pax3 in facial mesenchyme is main-
tained by signals from the overlying ectoderm. By stage 24,
residual Tbx2, Pea3, and Pax3 but not Erm expression is
maintained in the absence of such signals. Nevertheless,
refinement of the expression patterns and local modulation
of expression levels still require ectodermal signals, even at
stage 24. The pattern of Pax7 expression is not influenced
by ectodermal signals at any of the stages analyzed.
FGF8 Is Sufficient to Induce Expression of Tbx2,
Erm, Pea3, and Pax3 in Facial Mesenchyme
Since Fgf8 is expressed in the facial ectoderm in a pattern
that corresponds with the expression domains of Tbx2,
Erm, Pea3, and Pax3 in the underlying mesenchyme, we
investigated whether FGF protein is sufficient to substitute
for the ectoderm to maintain expression of these genes. For
this purpose, we isolated facial mesenchyme from stage 18
embryos and cultured it for 24 h in contact with heparin
acrylic beads that had been soaked in FGF8 protein (1 g/l,
FGF8 beads), PBS, or other growth factors. In explants
cultured with FGF8 beads, Tbx2 (n  25/25), Erm (n 
18/18), Pea3 (n  17/17), and Pax3 (n  20/20) RNA was
readily detectable in a halo around the beads, regardless of
where the beads had been placed on the explant (Figs.
4A–4D). For all four genes, similar results were obtained
with beads soaked in FGF4 (20/20 for each gene) or FGF9
protein (7/7 for each gene) and with FGF concentrations
between 50 ng/l and 1 g/l (data not shown). These
results are consistent with previous studies showing that
FGF4, -8, and -9 can substitute for each other in various
assays (Cohn et al., 1995; Crossley et al., 1996; Kettunen et
al., 1998; Neubu¨ser et al., 1997; Vogel et al., 1996). In
contrast, beads soaked in PBS (n  9 for each gene), FGF5,
FGF10, EGF, and IGF1 (n  3 for each gene) never did
induce expression of any of the genes studied (Figs. 4F–4J;
and data not shown). No Pax7 expression was ever observed
around FGF8 beads placed medially into the region nor-
mally devoid of Pax7 expression. Beads placed into the
lateral nasal region, where Pax7 is expressed independent of
ectodermal signals, occasionally resulted in a slight upregu-
lation of Pax7 expression but generally had no significant
effect on the level of Pax7 expression in mesenchyme close
to the bead (Fig. 4E, n  9/9). Together, these data show
that, at stage 18, FGF8 protein, as well as FGF4 and FGF9
proteins, are sufficient to maintain expression of Tbx2,
Erm, Pea3, and Pax3 in nasal mesenchyme. At that stage,
the mesenchyme in the midfacial region is uniformly
competent to respond to FGF signals by expressing these
genes.
We next examined whether FGF would still have an
effect on the expression of Tbx2, Erm, Pea3, and Pax3 at
stage 24 when Tbx2, Pea3, and Pax3 expression is no longer
completely dependent on ectodermal signals. In stage 24
mesenchyme cultured in contact with FGF8 beads for 24 h,
Tbx2 (n  10/10), Erm (n  9/9), Pea3 (n  8/8), and Pax3
(n 9/9) RNA was detected around the beads. However, the
level of induction was dependent on the position of the
bead. Beads placed into the lateral region, where Tbx2, Erm,
Pea3, and Pax3 are coexpressed with Fgf8 at high levels at
the time of explantation, resulted in a strong upregulation
of expression in the surrounding mesenchyme. In contrast,
only low levels of expression were detected around beads
FIG. 3. Expression of Tbx2, Erm, Pea3, Pax3, and Pax7 in nasal explants consisting of ectoderm and mesenchyme (stage 18, A–E; stage
24, P–T), mesenchyme (stage 18, F–J; stage 24, U–Y), and stage 18 mesenchyme with replaced ectoderm (K–O) after 24 h of culture in vitro.
E, ectoderm; m, mesenchyme; np, nasal placode.
FIG. 4. Expression of Tbx2, Erm, Pea3, Pax3, and Pax7 after application of FGF8- or PBS-soaked beads. (A–J) Stage 18 nasal mesenchyme
cultured for 24 h with FGF8 (A–E) or PBS (F–J) beads. (K–O) Stage 24 mesenchyme cultured for 24 h with FGF8 beads. (P–S) Embryo heads
after implantation of FGF-soaked beads at stage 18. (P) Tbx2 expression is extended dorsolaterally 8 h after implantation of an FGF8 bead
dorsolateral of the right nasal placode. (Q) Upregulation of Erm expression 24 h after implantation of an FGF4 bead dorsolateral of the right
nasal placode. (R) Upregulated Pea3 expression around an FGF4 bead 24 h after bead implantation dorsomedially of the right nasal placode.
(S) Extended Pax3 expression 20 h after implantation of two FGF4 beads dorsolaterally of the right nasal placode. (T) Pax3 expression 20 h
after implantation of a PBS-soaked bead into the right lateral region. Arrows label induced expression in the vicinity of the beads. m,
mesenchyme.
242 Firnberg and Neubu¨ser
© 2002 Elsevier Science (USA). All rights reserved.
placed into the medial region (Figs. 4K–4O). Expression of
Pax3 in particular was hardly detectable at all (Fig. 4N).
These data indicate that, at stage 24, competence of the
nasal mesenchyme to respond to FGF signaling is no longer
uniform. At that stage, FGF8 can still upregulate expression
of Tbx2, Erm, Pea3, and Pax3 laterally in the region
normally exposed to FGF8, but can only weakly induce
expression in medial mesenchyme, where Fgf8 is no longer
expressed in the overlying ectoderm.
Finally, in order to confirm the effect of FGF on the
expression of Tbx2, Erm, Pea3, and Pax3 in the context of
the living embryo, FGF4 or FGF8 beads were implanted
dorsolaterally or medially of the right nasal placode of stage
18–20 embryos in ovo. Embryos were then assayed for an
upregulation or ectopic expression in the vicinity of the
beads. In embryos dissected 8 or 24 h after FGF bead
implantation at stage 18–19, expression of Tbx2 (n  20),
Erm (n  7), and Pea3 (n  8) was upregulated around the
implanted beads and was also induced in areas that showed
no expression on the unmanipulated side (Figs. 4P–4R,
arrows; and data not shown). Implantation of FGF beads
also resulted in an extension of the Pax3 expression domain
(n  12). The effect, however, was much less pronounced
than for the other three genes and was restricted to beads
placed relatively close to the nasal placodes (Fig. 4S).
Implantation of PBS beads had no effect on the expression of
any of the four genes (Fig. 4T; and data not shown, n 5 per
gene). These results show that FGF beads can not only
substitute for facial ectoderm to maintain Tbx2, Erm, Pea3,
and Pax3 expression in facial mesenchyme in vitro, but can
induce ectopic expression of these genes in the facial area in
ovo.
FGF-Receptor Expression in the Nasal Region
between Stages 18 and 24
It has previously been reported that FGF receptors Fgfr1–
Fgfr3 are expressed during facial development (Wilke et al.,
1997). In order to assess whether changes in FGF receptor
expression might be responsible for the observed stage-
dependent change in competence of the nasal mesenchyme
to respond to FGF, we compared the expression of Fgfr1–
Fgfr3 at stages 18 and 24 by in situ hybridization. At stage
18, Fgfr1 was widely expressed in the nasal mesenchyme
and ectoderm, at uniform levels in the lateral and medial
nasal region (Fig. 5A). At that stage, expression of Fgfr2 was
below the level of detection (Fig. 5C). In contrast, at stage
24, expression of Fgfr1 in the lateral nasal process and at the
lateral edge of the medial nasal process was much higher
than expression close to the facial midline (Fig. 5B). Wide-
spread expression of Fgfr2 in the facial mesenchyme and
ectoderm with slightly stronger expression in the center of
the frontonasal mass was also detectable at that stage (Fig.
5D). Fgfr3 expression was undetectable in the nasal area at
both stages examined, but was detected in the developing
forebrain (data not shown). These results identify changes
in the expression of Fgfr1 as one possible cause for the
observed changes in competence of the mesenchyme to
respond to FGF8.
FGF Can Upregulate Expression of Erm and Pea3
in the Nasal Placode
Erm, Pea3, and Pax3 are not only expressed in facial
mesenchyme but also in the facial ectoderm overlapping
with Fgf8 expression. In addition, Erm and Pea3 are also
expressed throughout the nasal placode, which is sur-
rounded by Fgf8-expressing ectoderm but does not express
Fgf8 itself (Figs. 2B, 2H, and 2K). Pax3, in contrast, is only
expressed at the edge of the placode (Fig. 2N). In order to
explore whether Erm and Pea3 expression within the nasal
placode is regulated by FGF signaling, the central part of
stage 19 nasal placodes (using the developing olfactory
nerve as a landmark and aiming at excluding the Fgf8- and
Pax3-positive ectoderm surrounding the placode) was dis-
sected and cultured on top of stage 19 facial mesenchyme
for 24 h. In such explants, expression of Erm, Pea3, and
Pax3 in the nasal placode was undetectable after culture
(Figs. 6A–6C; n  8/8 for each gene). If, however, an FGF4
or FGF8 bead was placed next to the placode, expression of
Erm and Pea3 was readily detectable in the placode and the
mesenchyme surrounding the FGF bead (Figs. 6D, 6E, 6G,
and 6H, n  12/12 each). Pax3 expression, in contrast, was
only detectable in the mesenchyme but not in the nasal
placode (Figs. 6F and 6I, n 8/8 each). These results suggest
that expression of Pea3 and Erm in the nasal placode
requires the presence of the surrounding ectoderm and that
proximity to a source of FGF8, is sufficient for maintaining
and upregulating placodal Pea3 and Erm expression.
FGF Signaling Is Required for the Expression of
Tbx2, Erm, Pea3, and Pax3 in the Nasal Region
In order to examine whether FGF signaling is not only
sufficient but is also required for the maintenance of Tbx2,
Erm, Pea3, and Pax3 expression in the nasal region, we used
Su5402, a specific inhibitor of FGF signaling, to block FGF
signaling in explants cultured in vitro. Su5402 has previ-
ously been used to study the function of FGF signaling in
vitro and in ovo (Mohammadi et al., 1997; Muhr et al.,
1999; Norlin et al., 2000; Rodriguez Esteban et al., 1999;
Schneider et al., 1999; Wilson et al., 2000). Su5402 binds to
the ATP binding pocket of the FGF receptor kinase domain
and prevents receptor tyrosine phosphorylation by func-
tioning as a competitor to ATP. In the range of 10–200 M,
it did not inhibit tyrosine phosphorylation of the insulin
receptor or the EGF receptor, and only weakly inhibited the
PDGF receptor at high concentrations (Mohammadi et al.,
1997).
Facial explants consisting of ectoderm and mesenchyme
were isolated from embryos at stage 18 or stage 24 and
cultured for 8 h in the presence or absence of 25 M Su5402
in the culture medium. In stage 18 explants cultured in the
presence of Su5402, little or no expression of Tbx2 (n 
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10/10), Erm (n  9/10), Pea3 (n  7/7), and Pax3 (n  12/12)
was detectable at the end of the culture period (Figs. 7A–7D
and 7F–7I). In contrast, expression of Pax7 was still readily
detectable in the lateral region of explants cultured in the
presence of Su5402, albeit at slightly lower levels than in
controls (Figs. 7E and 7J, n  6/7). In order to exclude that
the failure to detect Tbx2, Erm, Pea3, and Pax3 RNA in
Su5402-treated explants is the consequence of a toxic effect
of Su5402 on the facial tissue (e.g., the induction of massive
cell death), we examined whether this loss of expression is
reversible. For this purpose, stage 18 explants were first
cultured for 8 h in the presence of Su5402 and then allowed
to recover for an additional 16 h in the absence of the
inhibitor. In such explants, expression of Tbx2 (n  11/11),
Erm (n 6/6), Pea3 (n 8/8), and Pax3 (n 6/6) was readily
detectable in similar patterns as in explants cultured in the
absence of the inhibitor throughout the 24-h culture period
(Figs. 7K–7N). These data therefore indicate that FGF sig-
naling is required for the maintenance of Tbx2, Erm, Pea3,
and Pax3 expression at stage 18.
In stage 24 explants cultured in the presence of Su5402,
expression of Tbx2 was still readily detectable. However, as
in stage 24 mesenchyme cultured in the absence of the
ectoderm, no upregulation of Tbx2 expression in the mes-
enchyme flanking the nasal placodes was observed (Figs. 7O
and 7T, n 4/4). Expression of Erm was barely detectable in
the mesenchyme of Su5402-treated explants, but expres-
sion in the nasal placodes was maintained (Figs. 7P and 7U,
n  6/7). Pea3 expression was undetectable in Su5402-
treated explants (Figs. 7Q and 7V, n 8/8). In contrast, Pax3
(n  6/6) and Pax7 (n  4/4) expression in Su5402-treated
explants was indistinguishable from the expression in con-
trol explants (Figs. 7R, 7S, 7W, and 7X). These results show
that, at stage 24, FGF signaling is not required for the
expression of Pax3 and Pax7 in facial mesenchyme. Upregu-
lation of Tbx2 in the nasal pit area and mesenchymal
expression of Erm and Pea3 still require FGF signaling at
this stage.
DISCUSSION
Ectodermal Signals Establish and Maintain
Spatially Restricted Gene Expression Patterns in
the Nasal Area
Studies on the function of signals and tissue interactions
in cultured tissue explants and mutant mice have recently
significantly increased our understanding of the mecha-
nisms involved in patterning the first branchial arch (BA1).
It is now a well-accepted idea that signals from the epithe-
FIG. 5. Expression of Fgfr1 and Fgfr2 in the nasal area at stages 18 and 24. Nonradioactive in situ hybridizations on transverse paraffin
sections through the nasal area. fb, forebrain; fnm, frontonasal mass; lnp, lateral nasal process; np, nasal placode.
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lium control both anterior–posterior and proximodistal
patterning of the early mouse BA1 (Jernvall and Thesleff,
2000; Tucker et al., 1998, 1999).
As in BA1, the mesenchyme in the nasal/midfacial region
is also derived from the neural crests but patterning of that
region is less well understood (Le Douarin, 1982; Noden,
1983; Osumi-Yamashita et al., 1994). Tissue recombination
and transplantation experiments in ovo had suggested that
outgrowth of the nasal mesenchyme depends on signals
from the overlying ectoderm (Wedden, 1987). Recently, a
study using mouse nasal explants has implicated FGF8,
SHH, and BMP4 as three ectodermal signals that act to-
gether to control patterning and cell differentiation in the
olfactory pathway (LaMantia et al., 2000). Here, we show
that expression of the transcription factors Tbx2, Erm,
Pea3, and Pax3 in nasal mesenchyme at stage 18 depends on
signals from the nasal ectoderm since expression of these
genes was lost in mesenchyme cultured in isolation. In
contrast, expression of Pax7 was maintained in nasal mes-
enchyme cultured for 24 h in the absence of the ectoderm.
These results show that, at stage 18, many aspects of
patterning of the nasal mesenchyme are still plastic and
require inductive signals from the ectoderm for mainte-
nance. This seems still to be true, although to a lesser
extent, even at stage 24. At that stage, ectodermal signals
are still required for the upregulation of expression of Tbx2,
Erm, and Pea3 in a horseshoe-shaped domain of mesen-
chyme surrounding the nasal pits.
On the other hand, an initial differential specification of
medial and lateral nasal mesenchyme seems already to have
occurred at stage 18, as indicated by the maintenance of
Pax7 expression in lateral nasal mesenchyme in the ab-
sence of the ectoderm. Whether this pattern of Pax7 expres-
sion is initially set up in response to inductive signals from
the ectoderm or whether it is the result of different origins
along the anterior–posterior axis of the neural crest cells
populating the lateral and the medial nasal region remains
to be examined. We detected Pax7 expression already in
streams of neural crest cells emigrating from the fore- and
midbrain into the lateral nasal region, and a similar pattern
of expression has also been described for a knock-in of LacZ
into the Pax7 locus in the mouse (Mansouri et al., 1996).
Pax7 may therefore already be expressed in prospective
lateral nasal cells before they reach the lateral nasal region.
Interestingly, our findings regarding the regulation of
Pax7 expression differ from the results described by LaMan-
FIG. 6. Erm and Pea3 expression in the nasal placode in response to FGF. Nasal placodes from stage 18 embryos were isolated carefully
excluding the Fgf8-expressing ectoderm surrounding them and cultured on top of stage 18 nasal mesenchyme (A–C). In (D–F), an
FGF4-soaked bead was placed next to the placodes. Erm is expressed at high levels in nasal placodes placed next to an FGF bead but not
in placodes cultured without one. Pea3 is induced in nasal placode next to an FGF bead to about the same levels as in the underlying nasal
mesenchyme. Pax3 is not normally expressed in the center of the nasal placodes and is not induced in placodes placed next to an FGF bead.
(G–I) Vibratome sections (30 m) of the explants shown in (D–F) clearly show the expression of Erm and Pea3 and the absence of Pax3
expression in the nasal placodes. Dashed circles label the positions of the placodes. Arrows mark expression induced in the nasal placodes.
Asterisk, FGF4 bead; m, mesenchyme; np, nasal placode.
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tia et al. (2000), who were unable to detect Pax7 expression
in E9.0 mouse nasal mesenchyme cultured for 48 h in the
absence of the nasal ectoderm. One possible explanation for
these apparently conflicting findings is the difference in the
length of culture, since the loss of Pax7 might be a late
consequence of the loss of inductive signals required, e.g.,
for the maintenance of lateral nasal fates. Alternatively,
differences in the developmental timing when the nasal
mesenchyme was isolated may also be responsible for the
differing results. In fact, E9.0 in the mouse may correspond
to a slightly younger stage in the chick than stage 18 used in
this study. Finally, species-specific difference in the regula-
tion of Pax7 expression can also not be ruled out.
FGF-Signaling Regulates Expression of Tbx2, Erm,
Pea3, and Pax3 in Nasal Mesenchyme
Using an FGF receptor antagonist, we have shown that, at
stage 18, FGF signaling is required to maintain expression
of these genes in nasal mesenchyme in the presence of the
ectoderm. Furthermore, beads soaked in recombinant
FGF4, -8, or -9 protein were sufficient to substitute for the
ectoderm to maintain expression of these genes in stage 18
nasal mesenchyme explanted in vitro, to upregulate expres-
sion of these genes in the nasal pit area of stage 24
mesenchyme explants, and to induce ectopic expression
when transplanted into the facial area of stage 18 embryos
in ovo. These results together strongly suggest that FGFs
produced in the nasal ectoderm regulate expression of Tbx2,
Erm, Pea3, and Pax3 in the underlying mesenchyme.
We have also shown that Fgf8 is expressed in a pattern
generally consistent with functioning as an epithelial signal
that regulates Tbx2, Erm, Pea3, and Pax3 expression in
vivo. However, the fibroblast growth factor family now
consists of 22 members (reviewed by Ornitz and Itoh, 2001;
Powers et al., 2000) and we have recently shown that 7
(Fgf3, Fgf8, Fgf9, Fgf10, Fgf15, Fgf17, and Fgf18) are ex-
pressed in partially overlapping domains during mouse
midfacial development (Bachler and Neubu¨ser, 2001). In
particular, Fgf9 and Fgf10 showed patterns that closely
resembled the Fgf8 expression pattern around the nasal
placodes. Both genes were, however, already expressed
lateral of the nasal placodes slightly earlier than Fgf8. In our
in vitro assay, FGF4, -8, and -9, but not FGF10, were all
equally sufficient to maintain expression of Tbx2, Erm,
Pea3, and Pax3, in line with previous studies showing that
FGF4, -8, and -9, but not FGF10, can perform the same
biological functions in a variety of developmental contexts
(Cohn et al., 1995; Crossley et al., 1996; Kettunen et al.,
1998; Neubu¨ser et al., 1997; Vogel et al., 1996). It is
therefore very likely that the expression of mesenchymal
targets of FGF signaling in the developing face is regulated
by the combined action of several members of the FGF
family, including both FGF8 and FGF9. Fgf9 has so far not
been cloned from the chick. Assuming that its expression
pattern in the chick resembles that in the mouse, FGF9
might be responsible for the early expression of Tbx2, Erm,
Pea3, and Pax3 in the lateral nasal region, when Fgf8
expression is still restricted to the medial nasal area. At
later stages, expression would then be maintained by both
FGF8 and FGF9 together. In other regions with coexpres-
sion of several FGFs, such as the midhindbrain boundary or
the apical ectodermal ridge of the limb bud, gene targeting
experiments have recently provided evidence for partially
redundant functions of different FGFs (Moon et al., 2000;
Sun et al., 2000; Xu et al., 2000). Knockouts of individual
members of the FGF family in the facial ectoderm may
therefore not result in a complete loss of expression of genes
that nevertheless require FGF signaling.
We found that expression of Tbx2, Erm, Pea3, and Pax3 is
induced around FGF beads within 4 h of bead application
(data not shown). This kinetic of induction is significantly
slower than the induction of Sprouty-2 by FGF, which has
been suggested to be a primary response target of FGF
signaling and is induced within 1 h after bead application
(Minowada et al., 1999). It is therefore currently unclear
whether any of the four genes analyzed is a direct target of
FGF signaling. Unfortunately, experiments aimed at ad-
dressing this possibility were unsuccessful due to poor
survival of early facial tissue in the presence of cyclohexi-
mide. Tbx2, Erm, Pea3, and Pax3 induction does, however,
occur quickly enough to act upstream of morphological
changes rather than being the consequence of pushing cell
differentiation into a particular direction.
Even though our results strongly point toward an essen-
tial function of FGF signaling in the regulation of Tbx2,
Erm, Pea3, and Pax3 expression during nasal development,
we cannot exclude that additional epithelial signals are
involved in the regulation of these genes. Such signals
could, e.g., modify the mesenchymal response to FGF by
synergizing with or antagonizing FGF signaling, as it has
been described for the antagonistic regulation of Pax9
expression by FGF and BMP signaling during tooth devel-
opment (Neubu¨ser et al., 1997). Our finding that Pax3
expression dorsomedial of the nasal pit was downregulated
in mesenchyme cultured in the absence of the ectoderm,
but maintained in explants consisting of ectoderm and
mesenchyme cultured in the presence of an FGF signaling
inhibitor in fact suggests that epithelial signals other than
FGF contribute to the regulation of Pax3 expression at that
stage. Likewise, we also found that some Pea3 expression
was maintained in stage 24 mesenchyme in the absence of
the ectoderm, whereas expression was completely lost in
explants consisting of mesenchyme and ectoderm in the
absence of FGF signaling. The regulation of Pea3 expression
therefore also seems to be more complex and may, for
example, involve inhibitory signals from the ectoderm that
downregulate Pea3 expression in the absence of FGF signal-
ing.
In all our experiments, FGF-soaked beads had no signifi-
cant effect on the expression of Pax7 in the nasal area, going
in line with our finding that the expression domain of Pax7
in the lateral nasal mesenchyme is maintained in the
absence of ectodermal signals. LaMantia et al. (2000) also
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studied the effect of FGF8 on Pax7 expression using a
somewhat different experimental set up. They describe that
the size of the Pax7 expression domain was expanded by
40% in E9.0 mouse nasal explants consisting of ectoderm
and mesenchyme cultured for 48 h in the presence of an
FGF8b function-blocking antibody. Conversely, in explants
that were cultured in the presence of 100 ng/ml FGF8b in
the medium, they found a 45% decrease in the Pax7
domain. A difference in the developmental timing when the
explants were isolated and the much longer culture time of
LaMania et al. (2000) are the most likely reasons why they
observe effects of FGF signaling on the Pax7 expression
domain, whereas we did not.
Stage Dependence of the Mesenchymal
Competence to Respond to FGF Signaling
We have found that the competence of the nasal mesen-
chyme to respond to FGF signaling by expression of Tbx2,
Erm, Pea3, and Pax3 is initially uniform. It therefore
appears that, at stage 18, the expression patterns of ectoder-
mal signals determine where these genes are expressed in
the mesenchyme. At later stages, however, mesenchyme in
the nasal pit region and the facial midline shows differential
responses. Whereas exposure of nasal pit mesenchyme to
FGF still results in a strong upregulation of expression, no
or only a weak induction is observed after exposure of
mesenchyme in the facial midline to FGF. Since Fgf8
expression disappears from midfacial ectoderm and be-
comes restricted to a horseshoe-shaped domain surrounding
the nasal pits by stage 24, only the mesenchyme that is still
exposed to FGF at that stage seems to maintain the com-
petence to respond to FGF signaling. Similar findings have
been described by Ferguson et al. (2000) for the mouse
mandibular arch. There, prior to E10.5, the mesenchyme
also proved to be equally competent to respond to FGF8 by
activating transcription of genes such as Dlx2, Dlx5, Msx1,
or Barx1. At a later stage, however, expression of these
genes could only be maintained within the endogenous
expression domains and ectopic expression could no longer
be induced. Therefore, the induction of regional gene ex-
pression in an initially equicompetent mesenchyme in
response to regional ectodermal signals seems to be a
common feature in patterning of the neural crest-derived
facial mesenchyme. We have found that expression of Fgfr1
is initially ubiquitous and uniform within the nasal mes-
enchyme but then becomes strikingly downregulated in
regions that lose competence. Therefore, changes in Fgfr
expression patterns may be one of the molecular alterations
that underlie the stage-dependent change in competence.
Further studies will be required to determine whether this
downregulation of Fgfr1 in the facial midline is necessary
and sufficient for the observed competence change or
whether additional alterations are also involved.
FGF Signaling Influences Gene Expression in the
Nasal Placodes
Between stages 18 and 24, Fgf8 is expressed at high levels
in the ectoderm adjacent to the nasal placodes, but not in
the placodes themselves. At the same time, Erm and Pea3
are expressed in the nasal placodes, the ectoderm surround-
ing them, and the nasal mesenchyme. Erm and Pea3 expres-
sion is downregulated in stage 18 nasal placodes cultured
separately from the Fgf8-positive ectoderm surrounding
them, but both genes are expressed at high levels in pla-
codes cultured adjacent to an FGF bead. In addition, Pea3
and Erm expression is also lost from the nasal placodes of
stage 18 explants cultured in the presence of Su5402.
Together, these observations strongly suggest that FGF
signaling regulates the expression of Pea3 and Erm in the
nasal placodes at stage 18. Whether FGF8 functions as a
planar signal that directly acts on the nasal placode ecto-
derm to control expression of Erm and Pea3 or whether it
exerts its effect indirectly via the induction of secondary
signals in the nasal mesenchyme remains to be investi-
gated.
The Role of Tbx2, Erm, Pea3, and Pax3 in
Midfacial Development
FGF signaling is essential for normal development of the
midfacial region. Embryos compound heterozygous for a
hypomorphic and a null allele of Fgf8 and embryos with a
tissue-specific knockout of Fgf8 in the facial area develop
severe midfacial malformations (Meyers et al., 1998; A.
Leibbrandt and M. Repitz, unpublished observations). Our
results clearly identify Tbx2, Erm, Pea3, and Pax3 as target
genes of FGF signaling in the nasal mesenchyme and
therefore suggest that these genes may function as direct or
indirect downstream mediators of FGF signaling in the face.
Mutations in PAX3 are responsible for the severe malfor-
mations in human patients with Waardenburg’s syndrome
(reviewed by Dahl et al., 1997). These patients typically
present craniofacial abnormalities, including dystopia can-
thorum, prominent nasal root, cleft lip and highly arched
palate, pigmentation deficiencies, and sensorineural deaf-
ness (McKusick, 1992). PAX3 is therefore essential for
normal development of cranial neural crest-derived struc-
tures. In the mouse, heterozygous Pax3 mutants (Splotch
mutants) show only in minor facial phenotypes (Asher et
al., 1996). Homozygous mutants, however, show gross
alterations of facial structures derived from the neural crest
but die at midgestation precluding analysis of the facial
skeleton (Auerbach, 1954). Since several examples of redun-
dancy among Pax genes belonging to the same subfamily
have been described, it cannot currently be ruled out that
Pax3 and Pax7 may serve partially redundant functions in
the lateral nasal region where they are coexpressed (Bou-
chard et al., 2000; Peters et al., 1999).
Mice in which the Tbx2 or Erm genes have been inacti-
vated are not yet available. Pea3-deficient mice are viable
and phenotypically normal, but males are infertile (Laing et
247FGF Targets in the Developing Face
© 2002 Elsevier Science (USA). All rights reserved.
al., 2000). Since Pea3, Erm, and Er81, the third member of
the Pea3 subfamily of Ets transcription factors, are struc-
turally closely related and expressed in very similar pat-
terns, partial redundancy between these genes can be ex-
pected (Chotteau-Lelievre et al., 1997; de Launoit et al.,
1997). The generation of double and triple mutants may
therefore be required to study their function in facial
development. A detailed analysis of the mutant phenotypes
of the targets of FGF signaling identified in this study, and
of their closely related genes, will ultimately contribute to
a better understanding of the role of FGF signaling during
midfacial development.
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